Enveric Biosciences, Inc.
ENVBEnveric Biosciences, Inc.
NASDAQ
Healthcare
Biotechnology
$2.03
-0.11(-5.14%)
52W $1.79 – $17.40
AI-generated
Enveric Biosciences, Inc.
$1MMkt Cap
—Rev TTM
-$19MNI TTM
-0.1xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 26, 2026Enveric Biosciences, Inc. reported a net loss of $8.8 million for fiscal year 2025, consistent with its pre-revenue biotech status. The company's operations were funded by raising approximately $10.5 million from sales of common stock and warrants. Total operating expenses were $8.8 million, comprising $5.8 million in general and administrative expenses and $2.8 million in research and development. The company...
What Changed Recently
Fundamentals
How The Business Makes Money
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Industry Biotechnology
Analyst View
Company Profile
CIK0000890821
ISINUS29405E5050
CUSIP29405E505
Phone239 302 1707
Address4851 Tamiami Trail North, Naples, FL, 34103, US
SEC EDGAR